ESMO 2017 | Combination therapy to treat ovarian cancer: promising results from the ANANOVA trial
Mansoor Mirza, MD, from the Copenhagen University Hospital, Copenhagen, Denmark discusses the results of the Phase I and II clinical trial ANANOVA (NCT02354131), a study which assessed the efficacy of niraparib alone in comparison to niraparib combined with bevacizumab in treating platinum-sensitive epithelial ovarian cancer. This study follows a previous trial, ANOVA (NCT01847274) which compared niraparib’s efficiency in treating ovarian cancer to standard chemotherapy. Dr Mirza tells us about the encouraging findings of the ANANOVA Phase I trial, and explains the structure and purpose of Phase II. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.
Get great new content delivered to your inboxSign up